Texas Permanent School Fund Corp Reduces Stock Position in Eli Lilly and Company $LLY

Texas Permanent School Fund Corp trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 33.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,205 shares of the company’s stock after selling 29,141 shares during the period. Eli Lilly and Company accounts for about 0.5% of Texas Permanent School Fund Corp’s holdings, making the stock its 19th largest holding. Texas Permanent School Fund Corp’s holdings in Eli Lilly and Company were worth $45,373,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $242,000. Brooklyn Investment Group lifted its position in Eli Lilly and Company by 32.4% in the first quarter. Brooklyn Investment Group now owns 6,881 shares of the company’s stock valued at $5,682,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Granite Harbor Advisors Inc. boosted its stake in Eli Lilly and Company by 67.9% in the first quarter. Granite Harbor Advisors Inc. now owns 2,084 shares of the company’s stock valued at $1,721,000 after acquiring an additional 843 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,062.67 on Tuesday. The stock has a fifty day moving average price of $943.82 and a 200 day moving average price of $822.76. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market cap of $1.00 trillion, a PE ratio of 51.99, a P/E/G ratio of 1.14 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Sanford C. Bernstein lifted their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research report on Monday, November 24th. Morgan Stanley raised their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,128.55.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.